^
Association details:
| Biomarker: | NOTCH1 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | icovamenib (BMF-219) (Menin-MLL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical activity of irreversible Menin inhibitor, BMF-219, in chronic lymphocytic leukemia.
Published date:
05/26/2022
Excerpt:
A comprehensive panel of CLL samples isolated from patients...Specimens isolated from patients with clinical profiles of high-risk genetic backgrounds associated with inferior outcomes to standard therapy, such as mutations in TP53 and NOTCH1, and chromosomal aberrations such as del(13q), trisomy 12 and complex karyotype, exhibited high sensitivity to BMF-219 treatment.
DOI:
10.1200/JCO.2022.40.16_suppl.7541
